A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia

David J. Kuter

Hematology Division, Massachusetts General Hospital, Boston

Katsuhiro Miura

Andrea Patriarca

Therapeutic Innovation in Hematology, Hematology Unit, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy

Dražen Pulanić

Division of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, and School of Medicine, University of Zagreb, Zagreb, Croatia

Atanas Radinoff

Department of Clinical Hematology, University Hospital St. Ivan Rilski, Sofia, Bulgaria

Katya Sapunarova

Division of Hematology, Department of Internal Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria

Antonia Syrigou

Hematology Department–BMT Unit, G Papanicolaou Hospital, Thessaloniki, Greece

Renchi Yang

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Van Anh Nguyen

Takeda Development Center Americas, Cambridge, MA

Emily Skelton

Takeda Development Center Americas, Cambridge, MA

Scarlett Wang

Takeda Development Center Americas, Cambridge, MA

Donald L. Yee

Takeda Development Center Americas, Cambridge, MA

Parth Patwari

Takeda Development Center Americas, Cambridge, MA